The aggregation of tau protein into paired helical filaments is one of the hallmarks of Alzheimer's disease and related dementias. We therefore continue our search for non-toxic, cell penetrating inhibitors of tau aggregation, which hold potential for brain penetration. have reported a high throughput screen for tau aggregation inhibitors previously, which resulted in the identification of several hit classes. Here we report the identification of novel inhibitors which were not present in the initial high throughput assay. This was achieved by transformation of the high throughput screen data into the 3D relationships of virtual pharmacophores The pharmacophore models were utilized in a virtual screen of a Maybridge database. The virtual screen provided 136 hits; 19 representative hits were selected and assayed, this resulted in two novel leads with an IC 50 < 13 M. These two leads feature a novel scaffold for tau aggregation inhibitors.
INTRODUCTION
The pathogenesis of Alzheimer's disease is under intensive investigation. Despite advances in the understanding, the exact cause is still unknown [1] . Clinical studies on Alzheimer's disease with post-mortem analysis have revealed that there are two major notable changes: a) The build-up of protein deposits known as amyloid plaques outside nerve cells through the enzymatic cleavage of the amyloid precursor protein, and b) The intracellular accumulation of neurofibrillary tangles [2] . The neurofibrillary tangles consist largely of an abnormal hyperphosphorylated form of the microtubule-associated protein tau [3] . The prevention of the tau aggregation into paired helical filaments (PHF) is a promising concept for causal treatment. Novel inhibitors which either prevent the accumulation of tau or dissolve existing aggregates are of great interest [4] . In our study, we started with a structure-activity relationship of selected tau inhibitors from different structural classes. Our aim was to identify novel leads for tau aggregation inhibition by scaffold hopping [5] . Using the software Catalyst™ (Accelrys Inc) we generated several pharmacophore based hypotheses which transformed the data into a three-dimensional relationship. The best models were utilized in a virtual screen of 59676 molecules from the Maybridge "Screening collection" database (October 2004) . The resulting hitlist of 136 compounds contained several new putative leads; 19 represen-*Address correspondence to this author at the Darmstadt Technical University, Clemens Schöpf-Institute for Organic Chemistry and Biochemistry, Petersenstrasse 22, D-64287 Darmstadt, Germany; Fax: 0049-6151 163278; E-mail: schmidt_boris@t-online.de tative compounds were selected and assayed, which resulted in the identification of two active lead structures with an IC 50 below 13 M.
METHODS
Ligand-based virtual screening has proven to be a versatile method to identify new ligands that display comparable biological activity but are based on a different scaffold [6] . Virtual screening applies computational tools to a known pharmacophore or a three-dimensional structure of a macromolecular target in order to select the most promising compounds from an electronic database for further synthesis and biological screening. In combination with other so called computer-based de novo design procedures virtual screening has emerged as a complementary concept to high-throughput screening efforts.
The pharmacophore modeling approach utilizing the programme Catalyst™ was applied successfully to several problems in medicinal chemistry [7] . Model building of the characteristic chemical features of different inhibitors is a critical task in the drug discovery process and has turned into a particular useful application for the virtual screening of large databases. Catalyst™ provides two ways of creating a pharmacophore model. The first algorithm, called HypoGen, uses an activity-based weighting scheme to build a chemical feature-based hypothesis. The second method, termed HipHop, identifies common pharmacophore patterns within a set of active molecules without using any activity data. In our approach we used the HypoGen algorithm, utilizing a training set of 21 different compounds within a range of activity ( Fig.  1 & Fig. 2) .
The selection of the training set compounds is a very important process in automated pharmacophore generation. In Catalyst™, the resulting models are strictly related to the input data [8] . There should be more than 18 molecules in the training set to ensure significance of the generated model. Furthermore, the selected structures should display the widest possible molecular diversity, resulting in orthogonal information. Similarly, the activity data for the set should span over 4 orders of magnitude. Each order should be represented by at least 3 molecules, where each compound provides new structural information. The most active compound should be in the training set to capture important chemical features and the biological data should be of the same quality. However, in practice there usually is no perfect data set at the beginning of a modeling project. Yet, one should consider these criteria for the selection of the training set [9] .
The training set of tau inhibitors used in this study was taken from the high throughput screen of 200,000 compounds [10] . A total of 1266 compounds were positive; 77 were even capable of dissolving preformed aggregates at low All structures were built and minimized within Catalyst™ using the function of 'best' conformer generation. A maximum of 250 conformers was generated within an energy range (85 kJ/mol) of the calculated potential energy minimum. 'Best' conformer generation should be used to build a hypothesis automatically from a training set of molecules [11] . HypoGen derived 10 pharmacophore hypotheses using the input data, from which a total of 3 hypotheses were chosen after manual review, and used to search the Maybridge database. The Maybridge "screening collection" (October 2004 Catalyst release, supplied by Accelrys) contained 59676 commercial available molecules, and was used without modification.
There are two algorithms in Catalyst™ to query databases. The 'Fast Flexible Search' command, which utilizes precalculated conformers present in the database, or the 'Best Flexible Search' command, which modifies the conformation of database members during calculation. Furthermore, Catalyst™ provides a value, which indicates how good a hit 'fits' to all features of a pharmacophore -a measure of hypothesis matching quality. In our approach we used a 'Minimum Fit' value of 3.5 and employed the 'Best Flexible Search' method which provides a subsequent energy minimization to optimize the fit onto a pharmacophore hypothesis.
EXPERIMENTAL SECTION Compounds
The compounds 1-21 were provided by Merck Darmstadt. The compounds 22-51 were acquired from Maybridge. The purity of the screening collection, was greater than 90% with the majority of compounds having a purity of 95% (see www.Maybridge.com).
Chemicals and Proteins
Heparin (average MW of 3000) and thioflavin-S (ThS) were obtained from Sigma. Tau construct K19 representing the repeat domain of tau (Fig. 3) was expressed in E. coli and purified by making use of the heat stability and FPLC Mono S (Pharmacia) chromatography as described [12] . PHF formation in vitro: Assembly of PHFs from tau protein (K19, 10 M) was performed at 37 °C in the presence of polyanions (heparin 2.5 M) in 50 mM NH 4 Ac, pH 6.8 as described elsewhere [13] . Assembly was followed quantitatively by fluorescence assay using thioflavin-S.
Screening of Tau Aggregation Inhibitors
The inhibition of PHF assembly and disassembly of preformed PHFs was measured as described previously [4] . Compound concentrations were chosen at 200 M, 60 M, 10 M down to 100 pM at a 10 M concentration of tau. Using 50 mM NH 4 Ac, 10 M protein (K19) and 2.5 M heparin were mixed in 50 l volume in a 384 well plate (black microtiter 384 plate round well, ThermoLabsystems, Dreieich, Germany) and incubated overnight at 37 °C. After incubation with the compounds thioflavin-S was added to a final concentration of 20 M and the signals were measured at excitation of 440 nm and emission of 521 nm in a spectrofluorimeter (Ascent; Labsystems, Frankfurt). All measurements were carried out three times.
Determination of Cell Toxicity of Compounds by Lactate Dehydrogenase (LDH) Assay
In order to discriminate the toxic effects on cells caused by the aggregation of tau it is necessary to determine the effects of the compounds by themselves. This can be done by the LDH release assay. An increase in the amount of damaged cells results in an increase of the LDH enzyme activity in the culture medium. The extent of cytotoxicity can be quantified photometrically at 500 nm due to the reduction of NAD + to NADH/H + in the medium and the subsequent conversion of tetrazolium salt (yellow) to formazan (red). Table  1 shows the cytotoxicity of the compounds belonging to the phenylthiazol-hydrazides (31 and 41 -51) of the 2 nd generation only. Measurements were performed 5 times. 100% cytotoxicity corresponds to cell treatment with 5% Triton X-100. The value of the untreated DMSO control is set as 0% cytotoxicity.
The bar diagrams show htau23, the fetal three repeat isoform of tau (compared with full-length tau it lacks the two N-terminal inserts and the second repeat in the microtubulebinding domain), and construct K19 containing the three repeats of the microtubule-binding domain.
RESULTS
Hypothesis generation was performed as described above -generating a total of 10 models for tau aggregation inhibitors. The resulting hypotheses contained four features with a varying numbers of hydrophobic regions, hydrogen bond acceptors and aromatic residues. The quality of each hypothesis was rated by computational activity estimation for each compound in the data set and comparison of the calculated activity to the experimentally determined binding constants. The same method was repeated with compounds outside the training set. To further validate the hypotheses, the two most active compounds were re-mapped, using the best flexible fit method. Good hypotheses should map the compounds in a chemically reasonable way. In other words, those hypotheses were considered to be the best, which demonstrated accurate estimated activities for conformers of low strain. Based on this evaluation criterion, three hypotheses were chosen to perform the database queries. All contain two aromatic rings, one hydrophobic region and one hydrogen bond acceptor (one example is shown in Fig. 5 ). In an attempt to improve the selectivity of our model, we manually added an additional hydrogen bond acceptor feature, based on public potent tau aggregation inhibitors -creating a 'five-feature' pharmacophore from the most promising automated four-feature model (Fig. 6) .
N o t F o r D i s t r i b u t i o n
Database queries were performed as described above. The 'Minimum fit' was set to 3.5 for the five-feature pharmacophore and to 4 for the other two four-feature models. Searching in this manner generated a hitlist of 136 potential tau aggregation inhibitors with common hits across all four screening models. Next, we clustered the compounds into different groups of related chemical functionality and selected 19 molecules at random for model validation. These compounds were screened in the ThS-assay for their ability to inhibit the aggregation of tau into paired helical filaments (1 st generation). The test is based on an aggregation assay, which exploits the fact that the dye thioflavin-S changes its spectral properties during the aggregation of tau [14] (Fig.  4) . Two of the selected compounds (31, 37) showed comparable activity to the best molecules from the training set (Fig.  7, Fig. 8 & Fig. 10). Four other compounds (25, 26, 32, 35) demonstrated activity, but displayed higher IC 50 s. The lead identification initiated a substructure search of one of the 2 active scaffolds (31) to provide a second generation from the Maybridge "screening collection" (Fig. 9) . The active compound 37 features a Michael-acceptor with a toxicity alert [15] , thus it was not pursued further.
Eleven derivatives of compound 31 were available from Maybrige, these were biologically assayed to validate our model further (2 nd generation). The average activity was approximately constant, but the hit rate improved (cut off at 20 M). The activities are shown in Fig. 9 & Fig. 11 . Fig. (7) . Selected hits 22-33.
The figure shows the results of the tau inhibition ThSassay with the compounds no. 30, 31 and 37 (see Fig. (7) and Fig. (8) ). For the test 10 M of the protein K19 was used in a dilution series of 200 M, 60 M and 1 M down to 100 pM of the respective compound.
The figure shows the results of the tau inhibition ThSassay with the compounds listed in Fig. (9) . For the test 10 M of the protein K19 was used in a dilution series of 200 M, 60 M and 1 M down to 100 pM of the respective compound.
CONCLUSION
We have demonstrated the value of ligand-based virtual screening for the identification of a novel scaffold from a small collection of compounds within the constraints of the Lipinski rules (s. Table 1 ). This is particularly important in the absence of a refined target structure. The identified compounds do not display sufficient activity to be regarded as drugs, but they are useful starting points for the development of tau aggregation inhibitors. We used a dataset of tau aggregation inhibitors with only partially known mode of action. Yet it is feasible to identify novel structures with potencies equalling the training set compounds. The described pharmacophore models will be refined to improve our understanding of the tau aggregation inhibitor structure-activity relationship. The two most active compounds have a toxicity alert associated with them, but several close analogues with somewhat weaker activity did not display any toxicity in the LDH assay. Thus the toxicity is not related to the scaffold. The optimisation of the lead structure for blood brain barrier penetration, toxicity, availability and selectivity towards other pathological protein deposits such as amyloid beta peptide (A ), prion protein associated with scrapie (PrP sc ) and -synuclein is ongoing. 
